Citation	Subject	Subject Label	Non grounded Subject	Potential MAXO	Predicate	Object	Object Label	Non grounded Object	Potential HP	Qualifier	Qualifier Label	Non grounded Qualifier	Potential MONDO	Subject Qualifier	Subject Extension	Object Extension	Count
10894210	maxo:0001001	gene therapy		[]	treats			canavan disease	[]				[]				1
11279290			(13)c magnetic resonance spectroscopy (mrs) technique	[('MAXO:0009070', 'SPECT')]	measures			increased [naa]	[]	mondo:0010079	canavan disease		[]				1
11279290			(13)c magnetic resonance spectroscopy (mrs) technique	[('MAXO:0009070', 'SPECT')]	measures			decreased [aspartate]	[]	mondo:0010079	canavan disease		[]				1
11279290	maxo:0000757	infusion		[]	investigates			synthesis rate	[('HP:0001370', 'RA')]	mondo:0010079	canavan disease		[]		chebi:17234	n-acetyl-l-aspartate (naa)	1
33892849			increased utilization of next generation sequencing	[]	treats			diagnosis	[]			leukodystrophies	[]		next generation sequencing		1
33892849			stem cell therapies	[]	treats	hp:0002415	leukodystrophies		[]				[]				1
33892849			transduction of autologous hematopoietic stem cells	[]	treats	hp:0002415	leukodystrophies		[]				[]	with lentiviral vectors	lentiviral vectors		1
33892849			ex vivo gene therapy	[('MAXO:0001001', 'gene therapy'), ('MAXO:0001298', 'therapy')]	treats			x-linked adrenoleukodystrophy	[('HP:0001417', 'X-linked')]			leukodystrophies	[]		gene therapy	x-linked adrenoleukodystrophy	1
33892849			ex vivo gene therapy	[('MAXO:0001001', 'gene therapy'), ('MAXO:0001298', 'therapy')]	treats			metachromatic leukodystrophy	[('HP:0002415', 'Leukodystrophy')]	mondo:0019046	leukodystrophies		[]	ex vivo	gene therapy		1
33892849			direct infusion	[('MAXO:0000757', 'infusion')]	treats			canavan disease	[]	mondo:0019046	leukodystrophies		[]	with adeno-associated virus vectors	adeno-associated virus vectors		1
33892849			rna therapies	[]	treats	hp:0003269	pelizaeus-merzbacher disease		[]	mondo:0019046	leukodystrophies		[]		rna therapies		1
33892849			small molecule therapies	[]	treats	hp:0002415	leukodystrophies		[]				[]				1
33892849			protein therapies	[]	treats	hp:0002415	leukodystrophies		[]				[]		protein therapies		1
33892849			intrathecal enzyme replacement therapy	[('MAXO:0001298', 'therapy')]	treats			metachromatic leukodystrophy	[('HP:0002415', 'Leukodystrophy')]	mondo:0019046	leukodystrophies		[]		enzyme replacement therapy		1
19294497			intracerebroventricular administration	[]	impairs			antioxidant defenses	[]	mondo:0010079	canavan disease		[]		chebi:21547		1
19294497			intracerebroventricular administration	[]	promotes			protein oxidation	[]	mondo:0010079	canavan disease		[]		chebi:21547		1
19294497			intracerebroventricular administration	[]	does not affect			oxidative stress parameters	[('HP:0025464', 'Oxidative stress')]	mondo:0010079	canavan disease		[]	with naag	chebi:73688		1
12718900			intracerebral injection	[]	treats			elevation of n-acetyl-l-aspartic acid	[]	mondo:0010079	canavan disease		[]		raav-haspa-gfp		1
12718900			gene transfer	[]	treats			spongiform degeneration	[]	mondo:0010079	canavan disease		[]	with raav-haspa-gfp	raav-haspa-gfp		1
12718900			magnetic resonance spectroscopy	[('MAXO:0009070', 'SPECT')]	prevents			increase of n-acetyl-l-aspartic acid	[]	mondo:0010079	canavan disease		[]		magnetic resonance spectroscopy	n-acetyl-l-aspartic acid	1
15775754			carrier screening panels	[('MAXO:0000530', 'carrier screening')]	prevents	hp:0003819	death in childhood		[]	mondo:0010100	tay-sachs disease		[]				1
15775754			carrier screening panels	[('MAXO:0000530', 'carrier screening')]	prevents	hp:0003819	death in childhood		[]			niemann-pick type a	[]				1
15775754			carrier screening panels	[('MAXO:0000530', 'carrier screening')]	prevents			moderate disability	[('HP:0012826', 'Moderate')]	mondo:0008876	bloom syndrome		[]				1
15775754			carrier screening panels	[('MAXO:0000530', 'carrier screening')]	prevents			moderate disability	[('HP:0012826', 'Moderate')]	mondo:0010079	canavan disease		[]				1
15775754			carrier screening panels	[('MAXO:0000530', 'carrier screening')]	prevents			moderate disability	[('HP:0012826', 'Moderate')]	mondo:0009061	cystic fibrosis		[]				1
15775754			carrier screening panels	[('MAXO:0000530', 'carrier screening')]	prevents			moderate disability	[('HP:0012826', 'Moderate')]	mondo:0009131	familial dysautonomia		[]				1
15775754			carrier screening panels	[('MAXO:0000530', 'carrier screening')]	prevents			moderate disability	[('HP:0012826', 'Moderate')]			fanconi anemia	[('MONDO:0002280', 'Fanconi Anemia'), ('MONDO:0002280', 'Fanconi anemia')]				1
15775754			carrier screening panels	[('MAXO:0000530', 'carrier screening')]	prevents			moderate disability	[('HP:0012826', 'Moderate')]	mondo:0009653	mucolipidosis type iv		[]				1
15775754			carrier screening panels	[('MAXO:0000530', 'carrier screening')]	prevents	hp:0000407	sensorineural hearing loss		[]			dfnb1 sensorineural hearing loss	[('MONDO:0017319', 'sensorineural hearing loss'), ('MONDO:0005365', 'sensorineural hearing loss')]				1
23622383			mri scan for diagnosis	[]	treats			neurological degradation	[]			leukodystrophies with astrocytic dysfunction	[('MONDO:0007113', 'AS'), ('MONDO:0042981', 'AS')]		mri scan		1
23622383	maxo:0000127	genetic testing		[]	treats	hp:0001355	megalencephaly		[]	mondo:0008752	alexander disease		[]		gfap mutations		1
23622383	maxo:0000127	genetic testing		[]	treats			white matter cystic breakdown	[]	mondo:0011380	cach/vwm		[]		eif2b mutations		1
23622383			genetic testing	[('MAXO:0000127', 'genetic testing')]	treats			spongiform cns degeneration	[('HP:0007009', 'CNS degeneration')]			leukodystrophies	[]		mlc1 mutations	astrocytic dysfunction	1
23622383			measurement of naa concentration in urine	[]	treats			neurological degradation	[]	mondo:0010079	canavan disease		[]	with naa	chebi:21547		1
24892353			monitoring of reproducibility	[]	prevents			misinterpretation	[('HP:0001658', 'MI')]			canavan disease	[('MONDO:0000001', 'Canavan disease'), ('MONDO:0000001', 'Canavan disease')]		mr spectroscopy system		1
24892353			change-point analysis	[]	prevents			misinterpretation	[('HP:0001658', 'MI')]	mondo:0010079	canavan disease		[]	in vitro	n-acetylaspartate levels		1
24892353			computation of ft factor	[]	treats			errors in interpretation	[]	mondo:0010079	canavan disease		[]	with n-acetylaspartate	n-acetylaspartate		1
24892353			application of ft coefficient to interpretation of in vivo spectra	[('MAXO:0009070', 'SPECT')]	treats			errors in interpretation	[]			canavan disease	[('MONDO:0000001', 'Canavan disease'), ('MONDO:0000001', 'Canavan disease')]		ft coefficient		1
10645473			creation of an animal model	[]	prevents			inability to hydrolyze naa	[]	mondo:0010079	canavan disease		[]				1
10645473			formulation of gene therapy	[('MAXO:0001001', 'gene therapy'), ('MAXO:0001298', 'therapy')]	prevents			spongy degeneration	[]	mondo:0010079	canavan disease		[]		gene therapy		1
16113575	maxo:0009003	preimplantation genetic diagnosis (pgd)		[]	prevents	hp:0001263	developmental delay		[]	mondo:0010079	canavan disease		[]				1
16113575	maxo:0009003	preimplantation genetic diagnosis (pgd)		[]	prevents			severe hypotonia	[('HP:0001252', 'Hypotonia'), ('HP:0012828', 'Severe')]	mondo:0010079	canavan disease		[]				1
16113575			preimplantation genetic diagnosis	[]	prevents			early death	[]			canavan disease	[('MONDO:0000001', 'Canavan disease'), ('MONDO:0000001', 'Canavan disease')]	na	na	na	1
28194442			gene replacement therapy	[('MAXO:0001298', 'therapy')]	treats			mutations in the aspartoacylase (aspa) gene	[]	mondo:0010079	canavan disease		[]		gene replacement therapy		1
28194442			gene replacement therapy	[('MAXO:0001298', 'therapy')]	treats			defect in n-acetylaspartate (naa) metabolism	[]			canavan disease	[('MONDO:0000001', 'Canavan disease'), ('MONDO:0000001', 'Canavan disease')]		gene replacement therapy		1
28194442			use of clinically translatable high-field imaging tools	[]	enables			noninvasive monitoring	[]	mondo:0010079	canavan disease		[]				1
21474353			safety trial of high dose glyceryl triacetate	[]	treats			excess accumulation of naa in the brain	[]	mondo:0010079	canavan disease		[]	high dose	chebi:9661		1
21474353			safety trial	[]	treats			deficiency of acetate necessary for myelin lipid synthesis	[]	mondo:0010079	canavan disease		[]	high dose	chebi:9661		1
21474353			intragastric administration of glyceryl triacetate	[]	treats			excess accumulation of naa in the brain	[]	mondo:0010079	canavan disease		[]	with glyceryl triacetate	chebi:9661		1
21474353			long-term efficacy study	[('MAXO:0000775', 'EFF')]	prevents			neurodegenerative disorder	[]	mondo:0010079	canavan disease		[]				1
19815695	maxo:0000530	genetic carrier screening		[]	prevents			misdiagnosis	[('HP:0001658', 'MI')]			genetic testing of disorders in people of ashkenazi jewish descent	[('MONDO:0000001', 'disorders'), ('MONDO:0000001', 'disorder')]				1
19815695			development of genomic dna reference materials	[]	supports			accurate testing	[]			genetic testing of disorders in people of ashkenazi jewish descent	[('MONDO:0000001', 'disorders'), ('MONDO:0000001', 'disorder')]		genomic dna reference materials		1
19815695			testing	[]	supports			accurate diagnosis	[]			genetic testing of disorders in people of ashkenazi jewish descent	[('MONDO:0000001', 'disorders'), ('MONDO:0000001', 'disorder')]	use of	dna from cell lines		1
19815695			testing in clinical laboratories	[]	supports			accurate diagnosis	[]			genetic testing of disorders in people of ashkenazi jewish descent	[('MONDO:0000001', 'disorders'), ('MONDO:0000001', 'disorder')]				1
19815695			genetic testing	[('MAXO:0000127', 'genetic testing')]	support			accurate detection	[]			disorders in people of ashkenazi jewish descent	[('MONDO:0000001', 'disorder'), ('MONDO:0000001', 'disorders')]		pcr-based assay platforms		1
19815695			quality control	[]	ensures			test reliability	[]			genetic testing of disorders in people of ashkenazi jewish descent	[('MONDO:0000001', 'disorders'), ('MONDO:0000001', 'disorder')]				1
19815695			proficiency testing	[]	ensures			tester competence	[]			genetic testing of disorders in people of ashkenazi jewish descent	[('MONDO:0000001', 'disorders'), ('MONDO:0000001', 'disorder')]				1
19815695			test development	[]	improves			diagnostic methods	[]			genetic testing of disorders in people of ashkenazi jewish descent	[('MONDO:0000001', 'disorders'), ('MONDO:0000001', 'disorder')]				1
19815695			research	[]	expands understanding in			genetic testing	[]			disorders in people of ashkenazi jewish descent	[('MONDO:0000001', 'disorder'), ('MONDO:0000001', 'disorders')]				1
11916483			gene delivery to the brain	[]	treats			metabolic deficiency	[]	mondo:0005071	neurologic disease		[]				1
11916483			gene delivery to the brain	[]	treats			degenerative conditions	[]	mondo:0005071	neurologic disease		[]				1
11916483			use of migratory cells	[]	treats			neurologic disease	[]				[]				1
11916483			facilitation of vascular delivery across the blood-brain barrier	[]	treats			neurologic disease	[]				[]				1
11916483			cerebrospinal fluid delivery	[]	treats			neurologic disease	[]				[]				1
11916483			convection injection	[]	treats			neurologic disease	[]				[]				1
11916483			gene delivery to the brain	[]	treats			neurologic disease	[]				[]	with adeno-associated virus	adeno-associated virus		1
11916483			gene delivery to the brain	[]	treats			neurologic disease	[]				[]	with lentivirus	lentivirus		1
11916483			gene delivery to the brain	[]	treats			neurologic disease	[]				[]	with gutless adenovirus	gutless adenovirus		1
11916483			gene delivery to the brain	[]	treats			neurologic disease	[]				[]	with herpes simplex virus hybrid amplicons	herpes simplex virus hybrid amplicons		1
27638987			pre-conception education and counselling	[]	prevents			transmission of ar conditions	[]			at-risk populations	[('MONDO:0008840', 'AT')]				1
27638987			pre-conception education and counselling	[]	prevents			transmission of ad conditions	[]			at-risk populations	[('MONDO:0008840', 'AT')]				1
27638987			pre-conception education and counselling	[]	prevents			transmission of xl conditions	[]			at-risk populations	[('MONDO:0008840', 'AT')]				1
27638987	maxo:0000530	genetic carrier screening		[]	prevents			transmission of disease	[]			cystic fibrosis, thalassemia, hemoglobinopathy, hemophilia, fragile x syndrome, spinal muscular atrophy	[('MONDO:0017319', 'muscular atrophy'), ('MONDO:0008974', 'spinal muscular atrophy')]	for conditions like			1
27638987			prenatal diagnosis	[]	treats			uncertainty	[]			autosomal recessive conditions	[('MONDO:0000001', 'condition'), ('MONDO:0008757', 'cond')]				1
27638987			preimplantation genetic diagnosis	[]	prevents			transmission of autosomal recessive conditions	[('HP:0000007', 'Autosomal recessive')]			at-risk populations	[('MONDO:0008840', 'AT')]				1
27638987			discussion about reproductive options including egg or sperm donation and adoption	[]	prevents			transmission of autosomal recessive conditions	[('HP:0000007', 'Autosomal recessive')]			at-risk populations	[('MONDO:0008840', 'AT')]				1
27638987			informing reproductive decisions	[]	prevents			transmission of autosomal recessive conditions	[('HP:0000007', 'Autosomal recessive')]			at-risk populations	[('MONDO:0008840', 'AT')]	based on	genetic carrier screening		1
11713764			gene transfer	[]	treats			spongiform degeneration of the brain	[]			canavan disease	[('MONDO:0000001', 'Canavan disease'), ('MONDO:0000001', 'Canavan disease')]		gene transfer		1
11713764			gene therapy strategy	[('MAXO:0001001', 'gene therapy'), ('MAXO:0001298', 'therapy')]	treats			spongiform degeneration of the brain	[]	mondo:0010079	canavan disease		[]				1
11713764			gene delivery systems	[]	treats			spongiform degeneration of the brain	[]	mondo:0010079	canavan disease		[]	with dcchol/dope-protamine	dcchol/dope-protamine		1
25066302			enzyme replacement therapy	[('MAXO:0001298', 'therapy')]	treats			fatal neurological disorder	[]	mondo:0010079	canavan disease		[]				1
25066302			producing a pegylated form of aspartoacylase	[]	treats			fatal neurological disorder	[]	mondo:0010079	canavan disease		[]	pegylated	aspartoacylase		1
25066302			achieving proper cellular targeting	[]	treats			fatal neurological disorder	[]	mondo:0010079	canavan disease		[]				1
25668701			promoting cd carrier screening	[('MAXO:0000530', 'carrier screening')]	prevents			canavan disease	[]			populations with high consanguineous marriages	[('MONDO:0007925', 'MAR'), ('MONDO:0009443', 'hi')]		cd carrier screening		1
25668701			developing customized molecular diagnostic approaches	[]	treats			canavan disease	[]			arab world	[]				1
30446350			rsv treatment	[]	treats			mutations in aspa gene	[]	mondo:0010079	canavan disease		[]				1
30446350			rsv treatment	[]	treats			deficiency in mitochondrial beta-oxidation	[('HP:0001427', 'Mitochondrial'), ('HP:0001427', 'mitochondrial')]			canavan disease	[('MONDO:0000001', 'Canavan disease'), ('MONDO:0000001', 'Canavan disease')]		rsv treatment		1
30446350			rsv treatment	[]	treats			deficiency in fatty acid beta-oxidation	[]	mondo:0010079	canavan disease		[]	with resveratrol	chebi:27881		1
16802706			gene transfer	[]	treats			spongy degeneration of the brain	[]	mondo:0010079	canavan disease		[]		adenoassociated virus mediated gene transfer		1
16802706			stem cell therapy	[('MAXO:0000016', 'cell therapy'), ('MAXO:0001298', 'therapy')]	treats			spongy degeneration of the brain	[]	mondo:0010079	canavan disease		[]				1
20034825			lithium administration	[]	treats			excessive intra-cerebral n-acetyl aspartate	[]	mondo:0010079	canavan disease		[]		chebi:30145		1
20034825			lithium administration	[]	improves			alertness	[]	mondo:0010079	canavan disease		[]	with lithium	chebi:30145		1
20034825			lithium administration	[]	improves			social interactions	[]	mondo:0010079	canavan disease		[]	with lithium	chebi:30145		1
20034825			lithium administration	[]	results in			mild improvement in myelination in the frontal white matter	[('HP:0001658', 'MI'), ('HP:0012825', 'Mild')]	mondo:0010079	canavan disease		[]	with lithium	chebi:30145		1
20034825			lithium administration	[]	suggests			micro-structural improvement in the corpus callosum	[('HP:0001658', 'MI')]	mondo:0010079	canavan disease		[]	with lithium	chebi:30145		1
33547378			genetic testing	[('MAXO:0000127', 'genetic testing')]	treats			clinical and neuroradiological findings suggestive of leukodystrophies	[]			leukodystrophies	[]				1
33547378			mutation testing in single genes	[]	treats			clinical and neuroradiological findings suggestive of leukodystrophies	[]	mondo:0019046	leukodystrophies		[]				1
33547378	maxo:0009004	whole exome sequencing (wes)		[]	treats			clinical and neuroradiological findings suggestive of leukodystrophies	[]	mondo:0019046	leukodystrophies		[]				1
33547378	maxo:0000127	genetic testing		[]	treats			clinical and neuroradiological findings suggestive of leukodystrophies	[]	mondo:0019046	leukodystrophies		[]				1
10820213			direct injection	[]	treats			absence-like seizure	[('HP:0001250', 'Seizure')]	mondo:0010079	canavan disease		[]		chebi:21547		1
10820213			direct injection	[]	treats			spongiform degeneration	[]	mondo:0010079	canavan disease		[]	with n-acetyl-l-aspartate	chebi:16953		1
31925837			intracisternal administration	[]	treats	hp:0001251	ataxia		[]	mondo:0010079	canavan disease		[]		locked nucleic acid antisense oligonucleotide		1
31925837			intracisternal administration	[]	treats			cerebellar and thalamic vacuolation	[]	mondo:0010079	canavan disease		[]		locked nucleic acid antisense oligonucleotide		1
31925837			intracisternal administration	[]	treats			purkinje cell dendritic atrophy	[]	mondo:0010079	canavan disease		[]		locked nucleic acid antisense oligonucleotide		1
16139832			ion-pairing hplc separation	[]	treats			low plasma levels of n-acetylaspartate	[]			inborn errors of metabolism (iem)	[('MONDO:0019052', 'inborn errors of metabolism'), ('MONDO:0019052', 'inborn errors of metabolism')]		ion-pairing hplc separation	n-acetylaspartate	1
16139832			ion-pairing hplc separation	[]	treats			dramatically high urinary n-acetylaspartate concentrations	[]			inborn errors of metabolism	[('MONDO:0019052', 'inborn errors of metabolism'), ('MONDO:0019052', 'inborn errors of metabolism')]		ion-pairing hplc separation		1
16139832			chemical diagnosis	[]	prevents			low plasma levels of n-acetylaspartate	[]	mondo:0019052	inborn errors of metabolism (iem)		[]		chemical diagnosis		1
16139832			chemical diagnosis	[]	prevents			dramatically high urinary n-acetylaspartate concentrations	[]	mondo:0019052	inborn errors of metabolism (iem)		[]		chemical diagnosis		1
16139832			screening	[]	prevents			low plasma levels	[]			inborn errors of metabolism (iem)	[('MONDO:0019052', 'inborn errors of metabolism'), ('MONDO:0019052', 'inborn errors of metabolism')]		iem screening	n-acetylaspartate	1
16139832			screening of iem	[]	prevents			dramatically high urinary n-acetylaspartate concentrations	[]	mondo:0019052	inborn errors of metabolism (iem)		[]				1
33138774			pre-test counselling	[]	prevents			misinterpretation of test results	[('HP:0001658', 'MI')]	mondo:0003847	genetic disorders		[]				1
33138774			ngs-based screening	[]	detects			congenital deafness	[('HP:0000365', 'Deafness')]	mondo:0003847	genetic disorders		[]				1
33138774			ngs-based screening	[]	detects			cystic fibrosis	[]			genetic disorders	[('MONDO:0000001', 'genetic disorder'), ('MONDO:0000001', 'disorder')]		ngs-based screening		1
33138774			ngs-based screening	[]	detects			pompe disease	[]	mondo:0003847	genetic disorders		[]				1
33138774			literature-based curation	[]	treats			misinformation	[('HP:0001658', 'MI')]	mondo:0003847	genetic disorders		[]				1
33138774			post-test counselling	[]	treats	hp:0000739	anxiety		[]	mondo:0003847	genetic disorders		[]				1
33138774			cascade screening	[]	prevents			further transmission	[]			genetic disorders	[('MONDO:0000001', 'genetic disorder'), ('MONDO:0000001', 'disorder')]	null	null	null	1
11783404			mri	[]	treats			diagnosis	[]			congenital white matter diseases and other neurodegenerative diseases	[('MONDO:0000001', 'neurodegenerative disease'), ('MONDO:0000001', 'neurodegenerative disease')]				1
25497124			biochemical and radiologic evaluation	[]	prevents			misdiagnosis	[('HP:0001658', 'MI')]	mondo:0010079	canavan disease		[]				1
25497124			dna sequencing	[]	treats			uncertainty of diagnosis	[]	mondo:0010079	canavan disease		[]				1
25497124			magnetic resonance imaging	[]	treats			misdiagnosis	[('HP:0001658', 'MI')]	mondo:0010079	canavan disease		[]				1
25497124			magnetic resonance spectroscopy	[('MAXO:0009070', 'SPECT')]	treats			diagnostic clarity	[]	mondo:0010079	canavan disease		[]	with n-acetyl aspartate, creatinine, choline	n-acetyl aspartate, creatinine, choline		1
23449113			vector-mediated gene transfer	[]	treats			canavan disease	[]	mondo:0010079	canavan disease		[]				1
23449113			vector-mediated gene transfer	[]	treats			batten disease	[]	mondo:0019262	batten disease		[]				1
23449113			vector-mediated gene transfer	[]	treats			adrenoleukodystrophy	[]			adrenoleukodystrophy	[('MONDO:0004975', 'adrenoleukodystrophy'), ('MONDO:0007088', 'adrenoleukodystrophy')]		vector-mediated gene transfer		1
23449113			vector-mediated gene transfer	[]	treats			parkinson's disease	[]	mondo:0005180	parkinson's disease		[]				1
14699612			development of a novel molecular diagnostic assay	[]	treats			canavan disease	[]				[]				1
14699612			low-cost, high-throughput population testing	[]	treats			canavan disease	[]				[]				1
14699612			multiplex fluorescent allele specific polymerase chain reaction (pcr)	[]	treats			canavan disease	[]				[]				1
17991069			mri scan	[]	treats			differential diagnosis	[]	mondo:0011925	merosin-negative congenital muscular dystrophy		[]				1
17991069	maxo:0000387	muscle biopsy		[]	treats			diagnosis confirmation	[]	mondo:0011925	merosin-negative congenital muscular dystrophy		[]	with immunohistochemical staining	immunohistochemical staining		1
17991069			mri scan	[]	treats			imaging differential diagnosis	[]			white matter diseases	[('MONDO:0000001', 'disease'), ('MONDO:0000001', 'disease')]	with gadolinium	chebi:33375		1
15464214			transplantation of neural progenitor cells	[('MAXO:0000068', 'transplantation')]	treats			spongy degeneration in the white matter	[]	mondo:0010079	canavan disease		[]		neural progenitor cells		1
15464214	maxo:0000068	transplantation		[]	treats			loss	[]	mondo:0010079	canavan disease		[]		neural progenitor cells	aspartoacylase synthesizing cells, oligodendrocytes	1
15515520			echo-planar diffusion mri examinations	[]	prevents			restricted diffusion pattern	[]			metabolic and toxic brain disorders	[('MONDO:0000001', 'disorder'), ('MONDO:0000001', 'disorders')]				1
15515520			echo-planar diffusion mri examinations	[]	prevents			elevated diffusion pattern	[]			metabolic and toxic brain disorders	[('MONDO:0000001', 'disorder'), ('MONDO:0000001', 'disorders')]		echo-planar diffusion mri examinations		1
15515520			echo-planar diffusion mri examinations	[]	prevents			mixed diffusion pattern	[('HP:0001658', 'MI')]			metabolic and toxic brain disorders	[('MONDO:0000001', 'disorder'), ('MONDO:0000001', 'disorders')]		echo-planar diffusion mri examinations		1
23727372			magnetic resonance imaging of the brain with spectroscopy	[('MAXO:0009070', 'SPECT')]	prevents			misdiagnosis	[('HP:0001658', 'MI')]			canavan disease	[('MONDO:0000001', 'Canavan disease'), ('MONDO:0000001', 'Canavan disease')]				1
23727372			chromatography of urinary organic acids	[]	treats			diagnostic uncertainty	[]			canavan disease	[('MONDO:0000001', 'Canavan disease'), ('MONDO:0000001', 'Canavan disease')]		chromatography		1
23727372			accumulation	[]	treats			none	[]	mondo:0010079	canavan disease		[]		n-acetyl aspartic acid	none	1
12524181			supplementation	[]	treats			acetate deficiency	[]	mondo:0010079	canavan disease		[]		chebi:30089		1
12524181			mutations in aspartoacylase	[]	causes			canavan disease	[]				[]				1
16138249			diagnosis	[]	treats	hp:0001252	hypotonia		[]	mondo:0010079	canavan disease		[]	based on elevated n-acetylaspartate in urine, reduced aspartoacylase activity in fibroblasts, and marked white matter changes on cerebral imaging			1
16138249			diagnosis	[]	treats	hp:0000256	macrocephaly		[]	mondo:0010079	canavan disease		[]	based on	n-acetylaspartate, aspartoacylase activity, white matter changes	elevated, reduced, marked	1
16138249	maxo:0000127	genetic testing		[]	treats			continuous psychomotor development without any regression	[]	mondo:0010079	canavan disease		[]		genetic analyses		1
16138249	maxo:0000127	genetic testing		[]	treats			mild developmental delay	[('HP:0001263', 'Developmental delay'), ('HP:0001658', 'Mild')]	mondo:0010079	canavan disease		[]				1
16138249	maxo:0000127	genetic testing		[]	treats			increased signal intensity in the basal ganglia	[('HP:0012824', 'Intensity')]	mondo:0010079	canavan disease		[]		genetic analyses		1
16138249	maxo:0000127	genetic testing		[]	treats			partial cortical blindness	[('HP:0000618', 'Cortical blindness'), ('HP:0000618', 'Blindness')]	mondo:0010079	canavan disease		[]				1
16138249	maxo:0000127	genetic testing		[]	treats	hp:0000510	retinitis pigmentosa		[]	mondo:0010079	canavan disease		[]				1
16138249			genetic analyses	[]	treats			slightly elevated n-acetylaspartate in the urine	[]			canavan disease	[('MONDO:0000001', 'Canavan disease'), ('MONDO:0000001', 'Canavan disease')]		genetic analyses		1
11589315			prenatal diagnosis	[]	prevents			clinical deterioration	[]	mondo:0010079	canavan disease		[]	with n-acetylaspartate	n-acetylaspartate		1
11589315			dna analysis	[]	prevents			clinical deterioration	[]			canavan disease	[('MONDO:0000001', 'Canavan disease'), ('MONDO:0000001', 'Canavan disease')]		dna analysis		1
11589315			control of seizures	[]	treats	hp:0001355	megalencephaly		[]	mondo:0010079	canavan disease		[]				1
11589315			gene therapy	[('MAXO:0001001', 'gene therapy'), ('MAXO:0001298', 'therapy')]	treats			white matter degeneration	[]			canavan disease	[('MONDO:0000001', 'Canavan disease'), ('MONDO:0000001', 'Canavan disease')]		gene therapy	white matter degeneration	1
19685155			tested tolerability	[]	treats			decreased brain acetate levels	[]	mondo:0010079	canavan disease		[]		chebi:9661		1
19685155			tested tolerability	[]	treats			reduced myelin lipid synthesis	[]	mondo:0010079	canavan disease		[]		chebi:9661		1
19685155			given orally	[]	treats			canavan disease	[]				[]	with glyceryl triacetate	chebi:9661		1
19685155			evaluation for toxicity	[]	prevents			potential adverse effects	[]	mondo:0010079	canavan disease		[]				1
14567959			screening	[]	prevents			progressive severe mental retardation	[('HP:0001249', 'Severe mental retardation'), ('HP:0003676', 'Mental retardation')]	mondo:0010079	canavan disease		[]		mutations		1
14567959			carrier testing	[]	prevents			progressive severe mental retardation	[('HP:0001249', 'Severe mental retardation'), ('HP:0003676', 'Mental retardation')]	mondo:0010079	canavan disease		[]				1
14567959			gene transfer trial	[]	treats			spongy degeneration of the brain	[]	mondo:0010079	canavan disease		[]	using adenoassociated virus (aav) as a vector	aspartoacylase gene transfer		1
18264947			carrier testing	[]	treats			n/a	[]			autosomal-recessive disorders	[('MONDO:0000001', 'disorder'), ('MONDO:0000001', 'disorders')]				1
18264947			genotyping assays	[]	prevents			n/a	[]			autosomal-recessive disorders	[('MONDO:0000001', 'disorder'), ('MONDO:0000001', 'disorders')]	n/a	n/a	n/a	1
19540689			proton mr spectroscopy	[('MAXO:0009070', 'SPECT')]	treats			elevated naa/cr ratio	[('HP:0001370', 'RA')]			inherited neurometabolic brain diseases	[('MONDO:0000001', 'disease'), ('MONDO:0000001', 'disease')]				1
19540689			proton mr spectroscopy	[('MAXO:0009070', 'SPECT')]	treats			galactitol peak at 3.7 ppm	[]			inherited neurometabolic brain diseases	[('MONDO:0000001', 'disease'), ('MONDO:0000001', 'disease')]		proton mr spectroscopy	galactitol peak at 3.7 ppm	1
19540689			proton mr spectroscopy	[('MAXO:0009070', 'SPECT')]	treats			branched chain amino acids at 0.9 ppm	[]			inherited neurometabolic brain diseases	[('MONDO:0000001', 'disease'), ('MONDO:0000001', 'disease')]				1
19540689			diffusion-weighted mr imaging	[]	treats			restricted diffusion	[]			inherited neurometabolic brain diseases	[('MONDO:0000001', 'disease'), ('MONDO:0000001', 'disease')]		mr imaging		1
23253610	maxo:0001001	gene therapy		[]	treats			accumulation in the brain	[]	mondo:0010079	canavan disease		[]		adeno-associated viral vector carrying the aspa gene (aav2-aspa)	n-acetyl-aspartate (naa)	1
23253610	maxo:0001001	gene therapy		[]	prevents			progression of brain atrophy	[('HP:0012444', 'Brain atrophy')]	mondo:0010079	canavan disease		[]		adeno-associated viral vector carrying the aspa gene (aav2-aspa)		1
23253610	maxo:0001001	gene therapy		[]	treats			seizure frequency	[('HP:0001250', 'Seizure'), ('HP:0040279', 'Frequency')]	mondo:0010079	canavan disease		[]		adeno-associated viral vector carrying the aspa gene (aav2-aspa)		1
32039588			kinetic modeling of the bold signal	[]	prevents			increased oxygen concentrations	[]			schizophrenia	[('MONDO:0005090', 'schizophrenia'), ('MONDO:0005090', 'schizophrenia')]		bold signal		1
32039588			analysis of biochemical data	[]	prevents			changes in the concentration of n-acetylaspartate	[]	mondo:0010079	canavan disease		[]				1
32039588			prediction of metabolite behavior	[]	prevents			superexcitation of the neural network	[]				[]	with n-acetylaspartate	n-acetylaspartate		1
32975148			case report	[]	prevents/treats	hp:0000256	macrocephaly		[]	mondo:0010079	canavan disease		[]				1
32975148			case report	[]	prevents/treats	hp:0001263	developmental delay		[]	mondo:0010079	canavan disease		[]				1
32975148			case report	[]	treats	hp:0001252	hypotonia		[]	mondo:0010079	canavan disease		[]				1
32975148			case report	[]	prevents/treats	hp:0000618	vision impairment		[]	mondo:0010079	canavan disease		[]				1
32975148			case report	[]	prevents/treats			severe vision loss	[('HP:0000572', 'Severe vision loss'), ('HP:0001141', 'Vision loss')]			canavan disease	[('MONDO:0000001', 'Canavan disease'), ('MONDO:0000001', 'Canavan disease')]				1
32975148			case report	[]	treats			accumulation of n-acetylaspartic acid	[]	mondo:0010079	canavan disease		[]		chebi:21547		1
32975148			case report	[]	treats			progressive white matter changes	[('HP:0003676', 'Progressive')]	mondo:0010079	canavan disease		[]				1
27531131			molecular modeling of mutation	[]	treats			not specified	[]	mondo:0010079	canavan disease		[]				1
32684374			viral-mediated gene replacement therapy	[('MAXO:0001298', 'therapy')]	treats			pediatric central nervous system neurogenetic disorders	[('HP:0030645', 'Central')]				[]	viral-mediated	gene replacement therapy	central nervous system neurogenetic disorders	1
32684374			clinical trials	[]	prevents			progression	[]			pediatric central nervous system neurogenetic disorders	[('MONDO:0000001', 'disorder'), ('MONDO:0000001', 'disorders')]				1
24577267			molecular proficiency testing	[]	treats			diagnostic ambiguity	[]	mondo:0010100	tay-sachs disease		[]	none	none	none	1
24577267			molecular proficiency testing	[]	treats			diagnostic ambiguity	[]	mondo:0010079	canavan disease		[]				1
24577267			molecular proficiency testing	[]	treats			diagnostic ambiguity	[]	mondo:0009131	familial dysautonomia		[]				1
24577267			genotyping	[]	treats			diagnostic ambiguity	[]	mondo:0010100	tay-sachs disease		[]				1
24577267			genotyping	[]	treats			diagnostic ambiguity	[]	mondo:0010079	canavan disease		[]				1
24577267			genotyping	[]	treats			diagnostic ambiguity	[]	mondo:0009131	familial dysautonomia		[]		genotyping		1
24577267			interpretations	[]	prevents			diagnostic errors	[]	mondo:0010100	tay-sachs disease		[]				1
24577267			interpretations	[]	prevents			diagnostic errors	[]	mondo:0010079	canavan disease		[]				1
24577267			interpretations	[]	prevents			diagnostic errors	[]	mondo:0009131	familial dysautonomia		[]				1
25781538			urine gc-ms analysis	[]	treats			inborn errors of metabolism	[]			iem	[]		gc-ms analysis		1
25781538			urease pretreatment	[]	treats			neonatal intrahepatic cholestasis caused by citrin deficiency	[('HP:0001396', 'Cholestasis'), ('HP:0001406', 'Intrahepatic cholestasis')]			inborn errors of metabolism	[('MONDO:0019052', 'inborn errors of metabolism'), ('MONDO:0019052', 'inborn errors of metabolism')]	for diagnosis	urease		1
27288788			non-genetic therapeutic approaches	[]	treats			diffuse spongiform white matter degeneration	[('HP:0020034', 'Diffuse')]	mondo:0010079	canavan disease		[]				1
27288788			non-genetic therapeutic approaches	[]	treats			dysmyelination	[]	mondo:0010079	canavan disease		[]				1
27288788			non-genetic therapeutic approaches	[]	treats			intramyelinic oedema	[('HP:0000969', 'Oedema')]	mondo:0010079	canavan disease		[]		non-genetic therapeutic approaches		1
27288788			non-genetic therapeutic approaches	[]	treats			impairment of psychomotor development	[]	mondo:0010079	canavan disease		[]		non-genetic therapeutic approaches		1
27288788			non-genetic therapeutic approaches	[]	treats			early death	[]	mondo:0010079	canavan disease		[]		non-genetic therapeutic approaches		1
27288788			non-genetic neuroprotective approaches	[]	treats			diffuse spongiform white matter degeneration	[('HP:0020034', 'Diffuse')]			canavan disease	[('MONDO:0000001', 'Canavan disease'), ('MONDO:0000001', 'Canavan disease')]		non-genetic neuroprotective approaches		1
27288788			non-genetic neuroprotective approaches	[]	treats			dysmyelination	[]	mondo:0010079	canavan disease		[]		non-genetic neuroprotective approaches		1
27288788			non-genetic neuroprotective approaches	[]	treats			intramyelinic oedema	[('HP:0000969', 'Oedema')]	mondo:0010079	canavan disease		[]		non-genetic neuroprotective approaches		1
27288788			non-genetic neuroprotective approaches	[]	treats			impairment of psychomotor development	[]	mondo:0010079	canavan disease		[]		non-genetic neuroprotective approaches		1
27288788			non-genetic neuroprotective approaches	[]	treats			early death	[]	mondo:0010079	canavan disease		[]		non-genetic neuroprotective approaches		1
16568890	maxo:0001001	gene therapy		[]	treats			hemophilia	[]	mondo:0018660	hemophilia		[]		recombinant aav (raav)		1
16568890	maxo:0001001	gene therapy		[]	treats			cystic fibrosis	[]	mondo:0009061	cystic fibrosis		[]		recombinant aav (raav)		1
16568890	maxo:0001001	gene therapy		[]	treats			alpha-1-antitrypsin deficiency	[]	mondo:0013282	alpha-1-antitrypsin deficiency		[]	using recombinant aav (raav)	recombinant aav (raav)		1
16568890	maxo:0001001	gene therapy		[]	treats			canavan disease	[]	mondo:0010079	canavan disease		[]		recombinant aav (raav)		1
20393311			dna testing	[]	treats			lack of diagnosis	[]			tay-sachs and canavan disease	[('MONDO:0000001', 'disease'), ('MONDO:0000001', 'disease')]				1
20393311			enzyme activity test	[]	treats			lack of diagnosis	[]			tay-sachs	[('MONDO:0017991', 'TA')]				1
20393311			genotyping	[]	treats			lack of diagnosis	[]			tay-sachs	[('MONDO:0017991', 'TA')]				1
20393311			preimplantation diagnosis	[]	treats			lack of diagnosis	[]			tay-sachs	[('MONDO:0017991', 'TA')]				1
20393311			confirmatory testing	[]	treats			lack of diagnosis	[]			tay-sachs	[('MONDO:0017991', 'TA')]				1
20393311	maxo:0000127	genetic testing		[]	treats			lack of diagnosis	[]			tay-sachs and canavan disease	[('MONDO:0000001', 'disease'), ('MONDO:0000001', 'disease')]				1
20393311	maxo:0000530	genetic carrier screening		[]	treats			lack of diagnosis	[]			tay-sachs and canavan disease	[('MONDO:0000001', 'disease'), ('MONDO:0000001', 'disease')]				1
26611604			gene therapy	[('MAXO:0001001', 'gene therapy'), ('MAXO:0001298', 'therapy')]	treats			metabolic disorders	[]			metabolic disorders	[('MONDO:0000001', 'metabolic disorder'), ('MONDO:0000001', 'disorder')]				1
12544239			diffusion magnetic resonance imaging (mri)	[]	assesses			restricted diffusion pattern	[]	mondo:0010079	canavan disease		[]				1
12544239			diffusion magnetic resonance imaging (mri)	[]	assesses			high signal on b = 1,000 mm2/s images	[]	mondo:0010079	canavan disease		[]				1
12544239			diffusion magnetic resonance imaging	[]	assesses			low apparent diffusion coefficient values	[]			canavan disease	[('MONDO:0000001', 'Canavan disease'), ('MONDO:0000001', 'Canavan disease')]		diffusion magnetic resonance imaging	low apparent diffusion coefficient values	1
12544239			diffusion magnetic resonance imaging (mri)	[]	assesses			edematous and gelatinous brain tissue	[('HP:0000969', 'Edema')]			canavan disease	[('MONDO:0000001', 'Canavan disease'), ('MONDO:0000001', 'Canavan disease')]	n/a	n/a	n/a	1
12544239			diffusion magnetic resonance imaging (mri)	[]	assesses			diffuse vacuolization	[('HP:0020034', 'Diffuse')]	mondo:0010079	canavan disease		[]				1
17149032			genetic testing	[('MAXO:0000127', 'genetic testing')]	prevents			genetic disorders	[]			ashkenazi jewish families	[('MONDO:0002056', 'FA'), ('MONDO:0100339', 'FA')]		genetic testing		1
17149032			counseling	[]	prevents			genetic disorders	[]			ashkenazi jewish families	[('MONDO:0002056', 'FA'), ('MONDO:0100339', 'FA')]				1
17149032			family planning	[]	prevents			genetic disorders	[]			ashkenazi jewish families	[('MONDO:0002056', 'FA'), ('MONDO:0100339', 'FA')]				1
25647544			urine excretion test for n-acetylaspartic acid	[]	diagnoses			increased urine excretion of n-acetylaspartic acid	[]	mondo:0010079	canavan disease		[]		chebi:21547		1
25647544			mutation screening	[]	confirms diagnosis in			diagnosis	[]			canavan disease	[('MONDO:0000001', 'Canavan disease'), ('MONDO:0000001', 'Canavan disease')]		aspa gene		1
22592512			initiation of lithium citrate	[]	treats			abnormal accumulation of n-acetyl aspartate (naa)	[]	mondo:0010079	canavan disease		[]		chebi:64735		1
22592512			hospitalization	[]	treats	hp:0002421	poor head control		[]	mondo:0010079	canavan disease		[]				1
22592512			hospitalization	[]	treats			decreased muscle tone	[]	mondo:0010079	canavan disease		[]				1
22592512			drug administration	[]	treats			abnormal accumulation of n-acetyl aspartate (naa)	[]	mondo:0010079	canavan disease		[]				1
22592512			drug administration	[]	treats	hp:0002421	poor head control		[]	mondo:0010079	canavan disease		[]				1
22592512			drug administration	[]	treats			decreased muscle tone	[]			canavan disease	[('MONDO:0000001', 'Canavan disease'), ('MONDO:0000001', 'Canavan disease')]		drug		1
20924741			mri	[]	prevents			typical alterations in mri	[]	mondo:0005066	metabolic disorders		[]				1
14582604			carrier testing	[]	prevents			autosomal-recessive disorders	[]				[]	with	dna-based assays		1
14582604			genetic consultation	[]	treats			carrier status	[]			autosomal-recessive disorders	[('MONDO:0000001', 'disorder'), ('MONDO:0000001', 'disorders')]				1
14582604			prenatal diagnosis	[]	treats			risk of offspring with autosomal-recessive disorders	[]				[]				1
14582604			evaluation of red cell indices and morphology	[]	treats			carrier detection	[]	mondo:0000984	thalassemias		[]				1
14582604			hematological testing	[]	treats			carrier detection	[]	mondo:0000984	thalassemias		[]				1
14582604			molecular analyses	[]	treats			carrier detection	[]	mondo:0000984	thalassemias		[]				1
17632691			quantification of n-acetylaspartic acid in urine by lc-ms/ms	[]	diagnoses			excessive excretion of n-acetylaspartic acid in urine	[]	mondo:0010079	canavan disease		[]		chebi:21547		1
17632691			hydrolysis of naa into acetate and l-aspartate	[]	prevents			excessive excretion of n-acetylaspartic acid in urine	[]	mondo:0010079	canavan disease		[]		hydrolysis		1
27039844			intracerebroventricularly delivered aspa gene therapy	[('MAXO:0001001', 'gene therapy'), ('MAXO:0001298', 'therapy')]	treats			immune impairments	[]	mondo:0016063	canavan disease (cd)		[]	intracerebroventricularly delivered	aspa gene therapy		1
27039844			intracerebroventricularly delivered aspa gene therapy (with recombinant adeno-associated viruses)	[('MAXO:0001001', 'gene therapy'), ('MAXO:0001298', 'therapy')]	treats			extended pathology beyond the central nervous system	[('HP:0030645', 'Central')]	mondo:0010079	canavan disease		[]	intracerebroventricularly delivered	aspa gene therapy	extended pathology beyond the central nervous system	1
27039844	maxo:0000144	histological examination		[]	identifies			morphological abnormalities	[]	mondo:0010079	canavan disease		[]				1
27039844			functional examination	[]	identifies			functional abnormalities	[]	mondo:0016063	canavan disease (cd)		[]				1
27039844			excessive accumulation	[]	causes			immune impairments	[]	mondo:0016063	canavan disease (cd)		[]		n-acetyl aspartic acid		1
29116375			gene replacement therapy	[('MAXO:0001298', 'therapy')]	treats			neurological decline	[]	mondo:0010079	canavan disease		[]		gene replacement therapy		1
29116375			gene replacement therapy	[('MAXO:0001298', 'therapy')]	treats			toxic naa accumulation	[]	mondo:0010079	canavan disease		[]		gene replacement therapy		1
29116375			gene replacement therapy	[('MAXO:0001298', 'therapy')]	treats			neurological deficits affecting unconscious defensive reactions	[]	mondo:0010079	canavan disease		[]	targeting oligodendrocytes	aspa gene replacement therapy		1
22611636			magnetic resonance imaging (mri)	[]	treats			diffuse white matter degeneration	[('HP:0020034', 'Diffuse')]	mondo:0010079	canavan disease		[]				1
22611636			magnetic resonance imaging (mri)	[]	treats			elevated excretion of urinary n-acetyl aspartic acid (naa)	[]	mondo:0010079	canavan disease		[]				1
15243987			carrier screening	[('MAXO:0000530', 'carrier screening')]	prevents			canavan disease	[]			ashkenazi jewish population in australia	[('MONDO:0007113', 'AS'), ('MONDO:0042981', 'AS')]				1
19235826			measuring n-acetylaspartate (naa) in amniotic fluid using liquid chromatography tandem mass spectrometry (lc-ms/ms)	[('MAXO:0009070', 'SPECT')]	prevents			diagnostic errors	[]	mondo:0010079	canavan disease		[]		chebi:21547		1
15149608			rapid and sensitive screening	[]	treats			abnormal naa level	[]	mondo:0010079	canavan disease		[]				1
15149608			chemical diagnosis	[]	treats			abnormal naa level	[]	mondo:0010079	canavan disease		[]	with n-acetylaspartate	n-acetylaspartate		1
15149608			gas chromatography-mass spectrometry (gc-ms)	[('MAXO:0009070', 'SPECT')]	treats			abnormal naa level	[]	mondo:0010079	canavan disease		[]	with n-acetylaspartate	n-acetylaspartate		1
15149608			pretreatment	[]	prevents			abnormal naa level	[]	mondo:0010079	canavan disease		[]		urease		1
16021451			diffusion-weighted mr imaging	[]	treats			major diffusion abnormalities	[]	mondo:0019046	leukodystrophies		[]		diffusion-weighted mr imaging		1
16021451			evaluation of conventional diffusion-weighted and adc map images	[]	treats			various edema types	[('HP:0000969', 'Edema')]	mondo:0019046	leukodystrophies		[]				1
16217711			proton magnetic resonance spectroscopy	[('MAXO:0009070', 'SPECT')]	treats			diffuse, symmetrical white matter degeneration in the subcortical areas	[('HP:0020034', 'Diffuse')]	mondo:0010079	canavan disease		[]				1
16217711			proton magnetic resonance spectroscopy	[('MAXO:0009070', 'SPECT')]	treats			bilateral involvement of the globus pallidus	[('HP:0012832', 'Bilateral')]	mondo:0010079	canavan disease		[]				1
16217711			proton magnetic resonance spectroscopy	[('MAXO:0009070', 'SPECT')]	treats			increase in the concentration of n-acetylaspartic acid	[]	mondo:0010079	canavan disease		[]		proton magnetic resonance spectroscopy	n-acetylaspartic acid (naa)	1
25311921			viral vector gene transfer	[]	treats			cns diseases	[]				[]				1
25311921			gene therapy approaches	[('MAXO:0001001', 'gene therapy'), ('MAXO:0001298', 'therapy')]	treats			cns diseases	[]				[]				1
22411242			diagnosis	[]	treats			neurologic problems	[]	mondo:0019046	leukodystrophies		[]				1
22411242			treatment	[]	treats			neurologic problems	[]	mondo:0019046	leukodystrophies		[]				1
22411242			prognostication	[]	treats			neurologic problems	[]	mondo:0019046	leukodystrophies		[]				1
23006656	maxo:0000016	cell therapy		[]	treats			myelin dysfunction	[]			metabolic leukodystrophies	[]				1
23006656			cell transplantation therapies	[('MAXO:0000068', 'transplantation')]	treats			cns and pns affectations	[]			metabolic leukodystrophies	[]		cell transplantation therapies		1
35187608			imaging diagnosis (with mri)	[]	treats			severe neurologic impairment	[('HP:0012828', 'Severe'), ('HP:0012828', 'Severe')]			canavan's spongiform leukodystrophy	[('MONDO:0004992', 'leukodystrophy'), ('MONDO:0012833', 'CA')]				1
35187608			imaging diagnosis	[]	treats	hp:0000256	macrocephaly		[]			canavan's spongiform leukodystrophy	[('MONDO:0004992', 'leukodystrophy'), ('MONDO:0012833', 'CA')]	with mr spectroscopy	mr spectroscopy		1
35187608			ultrasound	[]	treats			diffuse hyperechogenicity	[('HP:0020034', 'Diffuse')]			canavan's spongiform leukodystrophy	[('MONDO:0004992', 'leukodystrophy'), ('MONDO:0012833', 'CA')]				1
35187608			ultrasound	[]	treats			small multicystic changes of white matter	[]			canavan's spongiform leukodystrophy	[('MONDO:0004992', 'leukodystrophy'), ('MONDO:0012833', 'CA')]				1
35187608			ultrasound	[]	treats			inverted pattern of echogenicity between cortical gray and subcortical white matter	[]			canavan's spongiform leukodystrophy	[('MONDO:0004992', 'leukodystrophy'), ('MONDO:0012833', 'CA')]		ultrasound		1
12776232			ultrasound of the brain	[]	prevents			misdiagnosis	[('HP:0001658', 'MI')]	mondo:0010079	canavan disease		[]				1
17196380			magnetic resonance imaging	[]	treats			diffuse white matter degeneration	[('HP:0020034', 'Diffuse')]	mondo:0010079	canavan disease		[]				1
17196380			nuclear magnetic resonance spectroscopy	[('MAXO:0009070', 'SPECT')]	treats			diffuse white matter degeneration	[('HP:0020034', 'Diffuse')]	mondo:0010079	canavan disease		[]				1
17196380			gas chromatography-mass spectrometry	[('MAXO:0009070', 'SPECT')]	treats			diffuse white matter degeneration	[('HP:0020034', 'Diffuse')]	mondo:0010079	canavan disease		[]				1
20437087			investigation of in vitro and in vivo effects	[('MAXO:0000775', 'EFF')]	prevents			impairment of enzymatic antioxidant defenses	[]	mondo:0010079	canavan disease		[]		chebi:21547		1
20437087			n-acetylaspartic acid (with hydrogen peroxide)	[]	treats	hp:0010864	severe mental retardation		[]	mondo:0010079	canavan disease		[]	with hydrogen peroxide	chebi:21547		1
20437087			n-acetylaspartic acid (with hydrogen peroxide)	[]	treats	hp:0001252	hypotonia		[]	mondo:0010079	canavan disease		[]		chebi:21547	with hydrogen peroxide	1
20437087			n-acetylaspartic acid (with hydrogen peroxide) treatment	[]	treats			generalized tonic and clonic type seizures	[('HP:0001250', 'Seizure'), ('HP:0001250', 'Seizures')]	mondo:0010079	canavan disease		[]	with hydrogen peroxide	chebi:21547		1
22617649			oxidative stress	[]	precedes			oligodendrocyte loss	[]	mondo:0010079	canavan disease		[]				1
22617649			oxidative stress	[]	precedes			dysmyelination	[]	mondo:0010079	canavan disease		[]				1
38311564	maxo:0009004	whole exome sequencing (wes)		[]	treats			none	[]	mondo:0010079	canavan disease		[]				1
38311564			sanger sequencing	[]	treats			none	[]	mondo:0010079	canavan disease		[]				1
19888064	maxo:0000530	genetic carrier screening		[]	prevents			genetic diseases	[]			individuals of eastern european jewish descent	[('MONDO:0009133', 'JE'), ('MONDO:0019209', 'DES')]				1
34848132			newborn screening by tandem mass spectrometry (ms/ms)	[('MAXO:0009070', 'SPECT')]	prevents			unexplained convulsions	[]	mondo:0019052	inborn errors of metabolism (iem)		[]				1
34848132			newborn screening	[]	prevents			persistent metabolic acidosis	[('HP:0001941', 'Acidosis'), ('HP:0001942', 'Metabolic acidosis')]			inborn errors of metabolism	[('MONDO:0019052', 'inborn errors of metabolism'), ('MONDO:0019052', 'inborn errors of metabolism')]		tandem mass spectrometry		1
34848132			newborn screening	[]	prevents			persistent hypoglycemia	[('HP:0001943', 'Hypoglycemia')]			inborn errors of metabolism	[('MONDO:0019052', 'inborn errors of metabolism'), ('MONDO:0019052', 'inborn errors of metabolism')]		tandem mass spectrometry	persistent hypoglycemia	1
34848132			newborn screening	[]	prevents			disturbed consciousness	[]			inborn errors of metabolism (iems)	[('MONDO:0019052', 'inborn errors of metabolism'), ('MONDO:0019052', 'inborn errors of metabolism')]		tandem mass spectrometry		1
34848132			newborn screening	[]	prevents			delayed milestones	[('HP:0001263', 'Delayed milestones'), ('HP:0001658', 'MI')]			inborn errors of metabolism	[('MONDO:0019052', 'inborn errors of metabolism'), ('MONDO:0019052', 'inborn errors of metabolism')]		tandem mass spectrometry		1
34848132			proper specific management	[]	treats			unexplained convulsions	[]	mondo:0019052	inborn errors of metabolism (iem)		[]				1
34848132			proper specific management	[]	treats			persistent metabolic acidosis	[('HP:0001941', 'Acidosis'), ('HP:0001942', 'Metabolic acidosis')]	mondo:0019052	inborn errors of metabolism (iem)		[]				1
34848132			proper specific management	[]	treats			persistent hypoglycemia	[('HP:0001943', 'Hypoglycemia')]			inborn errors of metabolism (iems)	[('MONDO:0019052', 'inborn errors of metabolism'), ('MONDO:0019052', 'inborn errors of metabolism')]				1
34848132			proper specific management	[]	treats			disturbed consciousness	[]	mondo:0019052	inborn errors of metabolism (iem)		[]				1
34848132			proper specific management	[]	treats	hp:0001263	developmental delay		[]	mondo:0019052	inborn errors of metabolism (iem)		[]				1
16532510			gene delivery	[]	prevents			signs of inflammation	[]	mondo:0010079	canavan disease		[]	with raav-aspa	raav-aspa		1
16532510			intracranial infusions	[('MAXO:0000757', 'infusion')]	treats			canavan disease	[]				[]				1
16532510			monitoring immune response and safety profiles	[]	prevents			immune stimulation	[]	mondo:0010079	canavan disease		[]				1
16532510			monitoring immune response and safety profiles	[]	prevents	hp:0002383	brain inflammation		[]	mondo:0010079	canavan disease		[]				1
21095151			modification	[]	treats			fatal neurological disease	[]	mondo:0010079	canavan disease		[]		aspartoacylase		1
21095151			enzyme replacement therapy	[('MAXO:0001298', 'therapy')]	treats			fatal neurological disease	[]	mondo:0010079	canavan disease		[]		enzyme replacement therapy		1
21095151			administration of fully active modified enzymes	[]	reduces			elevated substrate levels	[]			canavan disease	[('MONDO:0000001', 'Canavan disease'), ('MONDO:0000001', 'Canavan disease')]		aspartoacylase	elevated substrate levels	1
23996800			acetate supplementation	[]	treats			epigenetic alterations	[]	mondo:0021042	glioma		[]	triacetin-based	chebi:9661		1
23996800			triacetin-based acetate supplementation	[]	treats			metabolic alterations	[]	mondo:0021042	glioma		[]		triacetin-based acetate supplementation		1
23996800			chemotherapeutic adjuvant therapy	[('MAXO:0001298', 'therapy')]	treats	hp:0009733	glioma		[]				[]	with triacetin	chebi:9661		1
23996800			chemotherapeutic adjuvant therapy	[('MAXO:0001298', 'therapy')]	treats	hp:0009733	glioma		[]				[]	with temozolomide	chebi:72564		1
23996800			growth-inhibitory effects assessment	[('MAXO:0000775', 'EFF')]	treats	hp:0009733	glioma		[]				[]	with triacetin	chebi:9661		1
23996800			cytostatic growth arrest induction	[]	treats	hp:0009733	glioma		[]				[]				1
23996800			survival extension	[]	treats	hp:0009733	glioma		[]				[]	with	triacetin and temozolomide		1
11818607			diffusion-weighted magnetic resonance imaging	[]	reveals			high adc and low aa in demyelination	[('HP:0011096', 'Demyelination')]			white matter diseases	[('MONDO:0000001', 'disease'), ('MONDO:0000001', 'disease')]				1
11818607			diffusion-weighted magnetic resonance imaging	[]	reveals			demyelinated white matter	[]			white matter diseases	[('MONDO:0000001', 'disease'), ('MONDO:0000001', 'disease')]		diffusion-weighted magnetic resonance imaging	low adc	1
12162821			neurosurgical delivery	[]	treats			increase in n-acetyl-aspartate (naa)	[]	mondo:0010079	canavan disease		[]		aspartoacylase gene (aspa) (with recombinant adeno-associated virus (aav))		1
12162821			neurosurgical delivery	[]	treats			impaired normal myelination	[]	mondo:0010079	canavan disease		[]	with recombinant adeno-associated virus (aav)	aspartoacylase gene (aspa)		1
12162821			neurosurgical delivery	[]	treats			spongiform degeneration of the brain	[]	mondo:0010079	canavan disease		[]	with recombinant adeno-associated virus (aav)	aspartoacylase gene (aspa)		1
10894262	maxo:0001001	gene therapy		[]	treats	hp:0010864	severe mental retardation		[]	mondo:0010079	canavan disease		[]		gene therapy		1
10894262	maxo:0001001	gene therapy		[]	treats			early death	[]	mondo:0010079	canavan disease		[]				1
10894262			electroporation to es cells	[]	prevents			neurological impairment	[]	mondo:0010079	canavan disease		[]				1
10894262			injection of es cells to blastocysts	[]	prevents	hp:0000256	macrocephaly		[]	mondo:0010079	canavan disease		[]		es cells		1
10894262			magnetic resonance imaging (mri)	[]	treats			generalized white matter disease	[('HP:0012837', 'Generalized')]	mondo:0010079	canavan disease		[]				1
10894262			spectroscopy (mrs)	[('MAXO:0009070', 'SPECT')]	treats			generalized white matter disease	[('HP:0012837', 'Generalized')]	mondo:0010079	canavan disease		[]				1
10894262			modulation of naa levels	[]	prevents			generalized white matter disease	[('HP:0012837', 'Generalized')]	mondo:0010079	canavan disease		[]		chebi:21547		1
20637282			increased global levels	[]	in			canavan disease	[]				[]		acetylated histone h3		1
20637282			increased	[]	in			canavan disease	[]				[]		gfap protein		1
15065127			supplementation	[]	treats			inadequate lipid/myelin synthesis during development	[]	mondo:0010079	canavan disease		[]		chebi:30089	inadequate lipid/myelin synthesis	1
26992473	maxo:0000127	genetic testing		[]	treats	hp:0001263	developmental delay		[]	mondo:0010079	canavan disease		[]				1
26992473			mri	[]	treats	hp:0001250	seizures		[]	mondo:0010079	canavan disease		[]				1
26992473			mri	[]	treats	hp:0000496	abnormal eye movements		[]	mondo:0010079	canavan disease		[]				1
26992473			mri	[]	treats	hp:0000252	microcephaly		[]	mondo:0010079	canavan disease		[]				1
15857674			aav-2-mediated aspartoacylase gene transfer	[]	treats			seizure phenotype	[('HP:0001250', 'Seizure')]	mondo:0010079	canavan disease		[]		aspartoacylase gene transfer		1
15857674			aav-2-mediated aspartoacylase gene transfer	[]	treats			generalized myelin vacuolation	[('HP:0012837', 'Generalized')]	mondo:0010079	canavan disease		[]	aav-2-mediated	aspartoacylase gene transfer		1
15857674			aav-2-mediated aspartoacylase gene transfer	[]	treats			severe motor and cognitive impairment	[('HP:0012828', 'Severe'), ('HP:0012828', 'Severe')]	mondo:0010079	canavan disease		[]		aspartoacylase		1
15857674			aav-2-mediated aspartoacylase gene transfer	[]	treats			elevated whole-brain naa levels	[]	mondo:0010079	canavan disease		[]	aav-2-mediated	aspartoacylase gene transfer	whole-brain naa levels	1
17219235			proton mr spectroscopy	[('MAXO:0009070', 'SPECT')]	treats			restricted diffusion	[]	mondo:0010079	canavan disease		[]		proton mr spectroscopy		1
17219235			elevated n-acetyl-l:-aspartate	[]	prevents			diagnosis	[]	mondo:0010079	canavan disease		[]		n-acetyl-l:-aspartate		1
25573156			acetate supplementation	[]	prevents			gsc proliferation	[]	mondo:0018177	glioblastoma (gbm)		[]		acetate supplementation		1
25573156			naa supplementation	[]	treats			gsc proliferation	[]	mondo:0018177	glioblastoma (gbm)		[]		naa supplementation	gsc proliferation	1
25573156			use of triacetin	[]	treats			poor prognosis	[]	mondo:0018177	glioblastoma (gbm)		[]		chebi:9661		1
25573156			treatment	[]	prevents			gsc proliferation	[]	mondo:0018177	glioblastoma (gbm)		[]		chebi:32954		1
25573156			use of triacetin (glyceryl triacetate, gta)	[]	treats			tumor recurrence	[('HP:0002664', 'Tumor')]	mondo:0018177	glioblastoma (gbm)		[]		chebi:9661		1
25573156			use of triacetin (glyceryl triacetate, gta)	[]	prevents			chemotherapy and radiation resistance	[('HP:0033567', 'RAD')]	mondo:0018177	glioblastoma (gbm)		[]	with triacetin (glyceryl triacetate, gta)	chebi:9661		1
28508091			mr spectroscopy	[('MAXO:0009070', 'SPECT')]	prevents			non-specific changes on mr	[]			metabolic disorders of the brain	[('MONDO:0000001', 'disorder'), ('MONDO:0000001', 'disorders')]		mr spectroscopy		1
28508091			mr spectroscopy	[('MAXO:0009070', 'SPECT')]	prevents			white substance lesions	[]			metabolic disorders of the brain	[('MONDO:0000001', 'disorder'), ('MONDO:0000001', 'disorders')]		mr spectroscopy		1
23331189	maxo:0001001	gene therapy		[]	treats			enzymatic deficiency	[]	mondo:0010079	canavan disease		[]				1
23331189			aadc gene delivery	[]	treats			parkinson's disease	[]				[]	with l-dopa	chebi:15765		1
23331189			gad gene delivery	[]	treats			parkinson's disease	[]				[]		gad gene delivery	with gaba	1
23331189			neurturin gene delivery	[]	treats			parkinson's disease	[]				[]				1
24036223			mri	[]	treats			clinical deterioration	[]	mondo:0010079	canavan disease		[]				1
24036223			biochemical analysis of naa in biological fluid samples	[]	treats			high naa excretion	[]	mondo:0010079	canavan disease		[]	with n-acetylaspartate	n-acetylaspartate		1
24036223			molecular biological examination	[]	treats			clinical deterioration	[]	mondo:0010079	canavan disease		[]				1
29170500			targeted gene therapy	[('MAXO:0001001', 'gene therapy'), ('MAXO:0001298', 'therapy')]	treats			canavan disease	[]	mondo:0010079	canavan disease		[]		aspartoacylase		1
22660905			mri brain	[]	treats			early onset developmental delay	[('HP:0001263', 'Developmental delay'), ('HP:0003674', 'Onset')]	mondo:0010079	canavan disease		[]				1
22660905			mri	[]	treats			initial hypotonia progressing to hypertonia	[('HP:0001252', 'Hypotonia'), ('HP:0001276', 'Hypertonia')]	mondo:0010079	canavan disease		[]		mri brain		1
22660905			mri brain	[]	treats	hp:0000256	macrocephaly		[]	mondo:0010079	canavan disease		[]				1
22660905			mri brain	[]	treats	hp:0000618	blindness		[]	mondo:0010079	canavan disease		[]				1
22660905			mr spectroscopy	[('MAXO:0009070', 'SPECT')]	treats			white matter changes	[]	mondo:0010079	canavan disease		[]	with n-acetyl aspartate	n-acetyl aspartate		1
16807907	maxo:0001001	gene therapy		[]	treats			lowering of n-acetyl l-aspartate	[]	mondo:0010079	canavan disease		[]	with aspa gene delivery	aspa gene delivery		1
16807907	maxo:0001001	gene therapy		[]	treats			change in motor functions	[]	mondo:0010079	canavan disease		[]	with aspa gene delivery	aspa gene delivery		1
16807907			aspa gene delivery	[]	fails to treat			sponginess of the wm	[]	mondo:0010079	canavan disease		[]				1
10909858			mutation detection	[]	treats			spongy degeneration of the brain	[]	mondo:0010079	canavan disease		[]		aspartoacylase gene		1
15074377			management of seizures	[]	treats	hp:0001250	seizures		[]	mondo:0010079	canavan disease		[]				1
15074377			management of spasticity	[]	treats	hp:0001257	spasticity		[]	mondo:0010079	canavan disease		[]	none	none	none	1
15074377			use of topiramate	[]	treats			enlargement of head	[]	mondo:0010079	canavan disease		[]	with topiramate	chebi:63631		1
20198415	maxo:0000127	genetic testing		[]	treats			allele dropout	[('HP:0000001', 'All')]			tay sachs disease	[('MONDO:0000001', 'disease'), ('MONDO:0000001', 'disease')]				1
20198415	maxo:0000127	genetic testing		[]	treats			allele dropout	[('HP:0000001', 'All')]	mondo:0009131	familial dysautonomia		[]				1
20198415	maxo:0000127	genetic testing		[]	treats			allele dropout	[('HP:0000001', 'All')]	mondo:0010079	canavan disease		[]				1
20198415			dna extraction	[]	treats			amplification failure	[]			tay sachs disease	[('MONDO:0000001', 'disease'), ('MONDO:0000001', 'disease')]		dna extraction		1
20198415			dna extraction	[]	treats			amplification failure	[]	mondo:0009131	familial dysautonomia		[]				1
20198415			dna extraction	[]	treats			amplification failure	[]	mondo:0010079	canavan disease		[]				1
20198415			single-cell based diagnosis	[]	treats			allele dropout	[('HP:0000001', 'All')]			tay sachs disease	[('MONDO:0000001', 'disease'), ('MONDO:0000001', 'disease')]				1
20198415			single-cell based diagnosis	[]	treats			allele dropout	[('HP:0000001', 'All')]			familial dysautonomia	[('MONDO:0001292', 'familial dysautonomia'), ('MONDO:0021809', 'dysautonomia')]		single-cell based diagnosis	allele dropout	1
20198415			single-cell based diagnosis	[]	treats			allele dropout	[('HP:0000001', 'All')]	mondo:0010079	canavan disease		[]				1
20198415			single-cell based diagnosis	[]	treats			amplification failure	[]			tay sachs disease	[('MONDO:0000001', 'disease'), ('MONDO:0000001', 'disease')]				1
20198415			single-cell based diagnosis	[]	treats			amplification failure	[]	mondo:0009131	familial dysautonomia		[]				1
20198415			single-cell based diagnosis	[]	treats			amplification failure	[]	mondo:0010079	canavan disease		[]				1
26586007	maxo:0000127	genetic testing		[]	treats			accumulation of n-acetylaspartate (naa)	[]	mondo:0010079	canavan disease		[]		genetic analysis		1
26586007			magnetic resonance imaging (mri)	[]	treats	hp:0007204	diffuse white matter abnormalities		[]	mondo:0010079	canavan disease		[]				1
26586007			magnetic resonance imaging (mri)	[]	treats			involvement of the basal ganglia	[]	mondo:0010079	canavan disease		[]				1
12443821	maxo:0000504	tracheostomy		[]	treats			chronic aspiration	[('HP:0002835', 'Aspiration'), ('HP:0011010', 'Chronic')]	mondo:0010079	canavan disease		[]				1
12443821	maxo:0000504	tracheostomy		[]	treats	hp:0002870	obstructive sleep apnea		[]	mondo:0010079	canavan disease		[]				1
17384215			comprehensive carrier screening	[('MAXO:0000530', 'carrier screening')]	prevents			na	[]	mondo:0010100	tay-sachs disease		[]	na	chebi:26708	na	1
17384215			comprehensive carrier screening	[('MAXO:0000530', 'carrier screening')]	prevents			na	[]	mondo:0008876	bloom syndrome		[]	na	chebi:26708	na	1
17384215			comprehensive carrier screening	[('MAXO:0000530', 'carrier screening')]	prevents			na	[]	mondo:0010079	canavan disease		[]				1
17384215			comprehensive carrier screening	[('MAXO:0000530', 'carrier screening')]	prevents			na	[]			niemann-pick a	[]	na	na	na	1
17384215			comprehensive carrier screening	[('MAXO:0000530', 'carrier screening')]	prevents			na	[]			familial dysautonomia	[('MONDO:0001292', 'familial dysautonomia'), ('MONDO:0021809', 'dysautonomia')]	na	na	na	1
17384215			comprehensive carrier screening	[('MAXO:0000530', 'carrier screening')]	prevents	hp:0001304	torsion dystonia		[]			na	[]	na	chebi:26708	na	1
17384215			comprehensive carrier screening	[('MAXO:0000530', 'carrier screening')]	prevents			na	[]	mondo:0009653	mucolipidosis type iv		[]				1
17384215			comprehensive carrier screening	[('MAXO:0000530', 'carrier screening')]	prevents			na	[]	mondo:0019391	fanconi anemia		[]	na	chebi:26708	na	1
17384215			comprehensive carrier screening	[('MAXO:0000530', 'carrier screening')]	prevents			na	[]	mondo:0018150	gaucher disease		[]	na	chebi:26708	na	1
17384215			comprehensive carrier screening	[('MAXO:0000530', 'carrier screening')]	prevents	hp:0001929	factor xi deficiency		[]			na	[]	na	chebi:26708	na	1
17384215			comprehensive carrier screening	[('MAXO:0000530', 'carrier screening')]	prevents			na	[]	mondo:0009287	glycogen storage disease type 1a		[]				1
17384215			comprehensive carrier screening	[('MAXO:0000530', 'carrier screening')]	prevents			na	[]	mondo:0009563	maple syrup urine disease		[]	na	chebi:26708	na	1
17384215			comprehensive carrier screening	[('MAXO:0000530', 'carrier screening')]	prevents			nonsyndromic sensorineural hearing loss	[('HP:0000365', 'Hearing loss'), ('HP:0000407', 'Sensorineural hearing loss')]			na	[]	na	na	na	1
17384215			comprehensive carrier screening	[('MAXO:0000530', 'carrier screening')]	prevents			na	[]	mondo:0018088	familial mediterranean fever		[]	na	chebi:26708	na	1
17384215			comprehensive carrier screening	[('MAXO:0000530', 'carrier screening')]	prevents			na	[]	mondo:0009291	glycogen storage disease type iii		[]				1
17384215			molecular diagnostic testing	[('MAXO:0000003', 'diagnostic testing')]	prevents			na	[]			tay-sachs disease	[('MONDO:0000001', 'Tay-Sachs disease'), ('MONDO:0000001', 'Tay-Sachs disease')]	na	na	na	1
17384215			molecular diagnostic testing	[('MAXO:0000003', 'diagnostic testing')]	prevents			na	[]	mondo:0008876	bloom syndrome		[]				1
17384215			molecular diagnostic testing	[('MAXO:0000003', 'diagnostic testing')]	prevents			na	[]	mondo:0010079	canavan disease		[]				1
17384215			molecular diagnostic testing	[('MAXO:0000003', 'diagnostic testing')]	prevents			na	[]			niemann-pick a	[]	na	chebi:26708	na	1
17384215			molecular diagnostic testing	[('MAXO:0000003', 'diagnostic testing')]	prevents			na	[]	mondo:0009131	familial dysautonomia		[]	na	chebi:26708	na	1
17384215			molecular diagnostic testing	[('MAXO:0000003', 'diagnostic testing')]	prevents			na	[]	mondo:0044843	torsion dystonia		[]				1
17384215			molecular diagnostic testing	[('MAXO:0000003', 'diagnostic testing')]	prevents			na	[]	mondo:0009653	mucolipidosis type iv		[]				1
17384215			molecular diagnostic testing	[('MAXO:0000003', 'diagnostic testing')]	prevents			na	[]	mondo:0019391	fanconi anemia		[]				1
17384215			molecular diagnostic testing	[('MAXO:0000003', 'diagnostic testing')]	prevents			na	[]	mondo:0018150	gaucher disease		[]				1
17384215			molecular diagnostic testing	[('MAXO:0000003', 'diagnostic testing')]	prevents			na	[]			factor xi deficiency	[('MONDO:0012897', 'factor XI deficiency'), ('MONDO:0020587', 'factor XI deficiency')]	na	na	na	1
17384215			molecular diagnostic testing	[('MAXO:0000003', 'diagnostic testing')]	prevents			na	[]	mondo:0009287	glycogen storage disease type 1a		[]				1
17384215			molecular diagnostic testing	[('MAXO:0000003', 'diagnostic testing')]	prevents			na	[]	mondo:0009563	maple syrup urine disease		[]	na	chebi:26708	na	1
17384215			molecular diagnostic testing	[('MAXO:0000003', 'diagnostic testing')]	prevents			nonsyndromic sensorineural hearing loss	[('HP:0000365', 'Hearing loss'), ('HP:0000407', 'Sensorineural hearing loss')]			na	[]	na	na	na	1
20393303			patenting	[]	prevents			genetic testing accessibility	[]	mondo:0003847	genetic disorders		[]				1
20393303			licensing	[]	prevents			genetic testing accessibility	[]			genetic disorders	[('MONDO:0000001', 'genetic disorder'), ('MONDO:0000001', 'disorder')]		licensing	genetic testing accessibility	1
22468686			family sequencing analysis	[]	prevents			severe motor and mental retardation	[('HP:0001249', 'Mental retardation'), ('HP:0012828', 'Severe')]	mondo:0010079	canavan disease		[]				1
22468686			prenatal diagnosis	[]	prevents			severe motor and mental retardation	[('HP:0001249', 'Mental retardation'), ('HP:0012828', 'Severe')]	mondo:0010079	canavan disease		[]				1
37597066			brain magnetic resonance imaging	[('MAXO:0000427', 'brain magnetic resonance imaging')]	diagnoses			progressive neurological disorders	[('HP:0003676', 'Progressive')]			leukodystrophies	[]		brain magnetic resonance imaging	progressive neurological disorders	1
37597066			single gene testing	[]	identifies			causal variant	[]	mondo:0019046	leukodystrophies		[]				1
37597066	maxo:0009004	whole exome sequencing (wes)		[]	identifies			causal variant	[]	mondo:0019046	leukodystrophies		[]				1
37597066			metabolic studies	[]	diagnose	hp:0002415	leukodystrophies		[]				[]				1
37597066			in silico analyses	[]	verify			pathogenicity of variants	[]	mondo:0019046	leukodystrophies		[]				1
17177147			proton magnetic resonance spectroscopy (1h-mrs)	[('MAXO:0009070', 'SPECT')]	monitors			abnormal accumulation of n-acetyl-aspartate (naa)	[]	mondo:0010079	canavan disease		[]		chebi:21547		1
17177147			diffusion-weighted mri	[]	monitors			changes in brain morphology	[]	mondo:0010079	canavan disease		[]				1
17177147			diffusion-weighted mri	[]	monitors			alterations in quantitative t1	[]	mondo:0010079	canavan disease		[]				1
17177147			diffusion-weighted mri	[]	monitors			variations in fractional anisotropy	[]	mondo:0010079	canavan disease		[]				1
17177147			diffusion-weighted mri	[]	monitors			adjustments in apparent diffusion coefficient	[]	mondo:0010079	canavan disease		[]				1
31839386			magnetic resonance imaging	[]	treats			intentional tremor	[('HP:0001337', 'Tremor'), ('HP:0001337', 'Tremor')]	mondo:0010079	canavan disease		[]				1
10894213			gene transfer	[]	treats			canavan disease	[]			canavan disease	[('MONDO:0000001', 'Canavan disease'), ('MONDO:0000001', 'Canavan disease')]		aspartoacylase gene transfer		1
10894213			use of lpd	[]	treats			canavan disease	[]				[]		non-viral lipid-entrapped, polycation-condensed delivery system		1
10894213			use	[]	treats			canavan disease	[]				[]		adeno-associated virus (aav)-based plasmids		1
10894213			intraventricular delivery	[]	treats			canavan disease	[]				[]				1
10894213			intravarenchymal injections	[]	treats			canavan disease	[]				[]				1
10894213			toxicity and expression testing	[]	prevents			adverse effects	[]			canavan disease treatment	[('MONDO:0000001', 'disease'), ('MONDO:0000001', 'disease')]				1
10894213			aspartoacylase gene transfer	[]	treats			canavan disease	[]				[]	with recombinant aspartoacylase	recombinant aspartoacylase		1
12108830			carrier detection	[]	prevents			canavan disease	[]	mondo:0010079	canavan disease		[]				1
12108830			prenatal diagnosis	[]	prevents			canavan disease	[]				[]	with molecular analysis	molecular analysis		1
12108830			prenatal diagnosis	[]	prevents			canavan disease	[]				[]	with analysis of amniotic fluid for naa	analysis of amniotic fluid for naa		1
15292027	maxo:0000530	carrier screening		[]	prevents			genetic diseases	[]	mondo:0010100	tay-sachs disease		[]				1
15292027	maxo:0000530	carrier screening		[]	prevents			genetic diseases	[]	mondo:0010079	canavan disease		[]				1
15292027	maxo:0000530	carrier screening		[]	prevents			genetic diseases	[]	mondo:0009061	cystic fibrosis		[]				1
15292027			carrier screening	[('MAXO:0000530', 'carrier screening')]	prevents			genetic diseases	[]			familial dysautonomia	[('MONDO:0001292', 'familial dysautonomia'), ('MONDO:0021809', 'dysautonomia')]		familial dysautonomia	genetic diseases	1
15292027			carrier screening	[('MAXO:0000530', 'carrier screening')]	prevents			genetic diseases	[]			mucolipidosis iv	[('MONDO:0009653', 'mucolipidosis IV'), ('MONDO:0009738', 'mucolipidosis I')]		mucolipidosis iv carrier screening		1
15292027	maxo:0000530	carrier screening		[]	prevents			genetic diseases	[]	mondo:0009756	niemann-pick disease type a		[]				1
15292027			carrier screening for fanconi anemia group c	[('MAXO:0000530', 'carrier screening')]	prevents			genetic diseases	[]			individuals of eastern european jewish descent	[('MONDO:0009133', 'JE'), ('MONDO:0019209', 'DES')]				1
15292027			carrier screening	[('MAXO:0000530', 'carrier screening')]	prevents			genetic diseases	[]			bloom syndrome	[('MONDO:0002254', 'Bloom syndrome'), ('MONDO:0007243', 'Bloom syndrome')]				1
15292027			carrier screening	[('MAXO:0000530', 'carrier screening')]	prevents			genetic diseases	[]			individuals of eastern european jewish descent	[('MONDO:0009133', 'JE'), ('MONDO:0019209', 'DES')]		gaucher's disease	genetic diseases	1
27077668			double fluorescence in situ hybridization	[]	prevents			lack of specific primary or secondary antibodies for immunostaining	[]	mondo:0010079	canavan disease		[]				1
27077668			immunolabelling	[]	prevents			lack of specific primary or secondary antibodies for immunostaining	[]	mondo:0010079	canavan disease		[]				1
27077668			immunostaining	[]	prevents			lack of specific primary or secondary antibodies for immunostaining	[]	mondo:0010079	canavan disease		[]				1
35929936	maxo:0009004	whole exome sequencing (wes)		[]	treats			diagnosis	[]	mondo:0010079	canavan disease		[]				1
35929936			sanger sequencing	[]	treats			diagnosis	[]	mondo:0010079	canavan disease		[]				1
35929936			prenatal diagnosis	[]	prevents			transmission	[]			canavan disease	[('MONDO:0000001', 'Canavan disease'), ('MONDO:0000001', 'Canavan disease')]		chorionic villi sampling (cvs)		1
35929936			urine metabolism screening	[]	treats			elevated n-acetylaspartic acid	[]	mondo:0010079	canavan disease		[]	with n-acetylaspartic acid	chebi:21547		1
35929936			cranial magnetic resonance imaging	[]	treats			diagnosis	[]	mondo:0010079	canavan disease		[]				1
15337171			investigation	[]	treats	hp:0001138	optic neuropathy		[]	mondo:0010079	canavan disease		[]		nadc3 and aspartoacylase ii expression		1
15337171			in situ hybridization	[]	treats	hp:0001138	optic neuropathy		[]	mondo:0010079	canavan disease		[]				1
16854607			self-ligation	[]	treats			large deletions	[]			canavan disease	[('MONDO:0000001', 'Canavan disease'), ('MONDO:0000001', 'Canavan disease')]		restriction endonuclease-digested dna fragments with long-distance inverse pcr		1
16854607			genomic dna	[]	treats			large deletions	[]	mondo:0010079	canavan disease		[]	not specified	multiplex dosage quantitative pcr analysis	large deletions	1
20464498			supplementation	[]	treats			impaired myelination	[]	mondo:0010079	canavan disease		[]		chebi:30089		1
20464498			administered orally	[]	treats			brain vacuolation	[]	mondo:0010079	canavan disease		[]		glyceryltriacetate (gta)		1
20464498			administered orally	[]	treats			diminished motor function	[]	mondo:0010079	canavan disease		[]		glyceryltriacetate (gta)		1
20464498			administered orally	[]	treats			severe phenotype	[('HP:0012828', 'Severe'), ('HP:0012828', 'Severe')]	mondo:0010079	canavan disease		[]		glyceryltriacetate (gta)		1
